October 16, 2015

Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26

October 16, 2015 11:54 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will report financial results for the third quarter of 2015… Read More
learn more
October 16, 2015

Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26

October 16, 2015 11:54 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will report financial results for the third quarter of 2015… Read More
learn more
October 9, 2015

ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients… Read More
learn more
October 9, 2015

ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients… Read More
learn more
October 9, 2015

ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients… Read More
learn more
October 7, 2015

NovoCure Limited Announces Closing of Initial Public Offering

October 07, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares… Read More
learn more
October 7, 2015

NovoCure Limited Announces Closing of Initial Public Offering

October 07, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares… Read More
learn more
October 7, 2015

NovoCure Limited Announces Closing of Initial Public Offering

October 07, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares… Read More
learn more
October 5, 2015

Novocure Announces CE Mark and First Patient Use of Second Generation Optune System

The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50% lighter and 50% smaller than the first generation system The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50%… Read More
learn more
October 5, 2015

Novocure Announces CE Mark and First Patient Use of Second Generation Optune System

The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50% lighter and 50% smaller than the first generation system The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50%… Read More
learn more